Research programme: chronic pain therapies - Apricus BiosciencesAlternative Names: Lidocaine - Apricus Biosciences; Lidocaine/prilocaine - Apricus Biosciences; NM 30088
Latest Information Update: 16 Jul 2016
At a glance
- Originator NexMed
- Developer Apricus Biosciences
- Mechanism of Action Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pain